Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain

Jennifer M. Yentes, Jessie M. Huisinga, Sara A Myers, Iraklis I Pipinos, Jason M Johanning, Nicholas Stergiou

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Peripheral arterial disease (PAD) is a manifestation of atherosclerosis resulting in intermittent claudication (IC) or leg pain during physical activity. Two drugs (cilostazol and pentoxifylline) are approved for treatment of IC. Our previous work has reported no significant differences in gait biomechanics before and after drug interventions when PAD patients walked without pain. However, it is possible that the drugs are more efficacious during gait with pain. Our aim was to use advanced biomechanical analysis to evaluate the effectiveness of these drugs while walking with pain. Initial and absolute claudication distances, joint kinematics, torques, powers, and gait velocity during the presence of pain were measured from 24 patients before and after 12 weeks of treatment with either cilostazol or pentoxifylline. We found no significant improvements after 12 weeks of treatment with either cilostazol or pentoxifylline on the gait biomechanics of PAD patients during pain. Our findings indicate that the medications cilostazol and pentoxifylline have reduced relevance in the care of gait dysfunction even during pain in patients with PAD.

Original languageEnglish (US)
Pages (from-to)184-191
Number of pages8
JournalJournal of applied biomechanics
Volume28
Issue number2
DOIs
StatePublished - May 2012

Fingerprint

Intermittent Claudication
Gait
Pentoxifylline
Pharmacology
Peripheral Arterial Disease
Pain
Biomechanical Phenomena
Pharmaceutical Preparations
Therapeutics
Torque
Walking
Leg
Atherosclerosis
Joints
Exercise
cilostazol

Keywords

  • Biomechanics
  • Cilostazol
  • Locomotion
  • Pentoxifylline
  • Peripheral arterial disease

ASJC Scopus subject areas

  • Biophysics
  • Orthopedics and Sports Medicine
  • Rehabilitation

Cite this

@article{f29de6a488c04fc2a7971297a58f65c7,
title = "Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain",
abstract = "Peripheral arterial disease (PAD) is a manifestation of atherosclerosis resulting in intermittent claudication (IC) or leg pain during physical activity. Two drugs (cilostazol and pentoxifylline) are approved for treatment of IC. Our previous work has reported no significant differences in gait biomechanics before and after drug interventions when PAD patients walked without pain. However, it is possible that the drugs are more efficacious during gait with pain. Our aim was to use advanced biomechanical analysis to evaluate the effectiveness of these drugs while walking with pain. Initial and absolute claudication distances, joint kinematics, torques, powers, and gait velocity during the presence of pain were measured from 24 patients before and after 12 weeks of treatment with either cilostazol or pentoxifylline. We found no significant improvements after 12 weeks of treatment with either cilostazol or pentoxifylline on the gait biomechanics of PAD patients during pain. Our findings indicate that the medications cilostazol and pentoxifylline have reduced relevance in the care of gait dysfunction even during pain in patients with PAD.",
keywords = "Biomechanics, Cilostazol, Locomotion, Pentoxifylline, Peripheral arterial disease",
author = "Yentes, {Jennifer M.} and Huisinga, {Jessie M.} and Myers, {Sara A} and Pipinos, {Iraklis I} and Johanning, {Jason M} and Nicholas Stergiou",
year = "2012",
month = "5",
doi = "10.1123/jab.28.2.184",
language = "English (US)",
volume = "28",
pages = "184--191",
journal = "Journal of Applied Biomechanics",
issn = "1065-8483",
publisher = "Human Kinetics Publishers Inc.",
number = "2",

}

TY - JOUR

T1 - Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain

AU - Yentes, Jennifer M.

AU - Huisinga, Jessie M.

AU - Myers, Sara A

AU - Pipinos, Iraklis I

AU - Johanning, Jason M

AU - Stergiou, Nicholas

PY - 2012/5

Y1 - 2012/5

N2 - Peripheral arterial disease (PAD) is a manifestation of atherosclerosis resulting in intermittent claudication (IC) or leg pain during physical activity. Two drugs (cilostazol and pentoxifylline) are approved for treatment of IC. Our previous work has reported no significant differences in gait biomechanics before and after drug interventions when PAD patients walked without pain. However, it is possible that the drugs are more efficacious during gait with pain. Our aim was to use advanced biomechanical analysis to evaluate the effectiveness of these drugs while walking with pain. Initial and absolute claudication distances, joint kinematics, torques, powers, and gait velocity during the presence of pain were measured from 24 patients before and after 12 weeks of treatment with either cilostazol or pentoxifylline. We found no significant improvements after 12 weeks of treatment with either cilostazol or pentoxifylline on the gait biomechanics of PAD patients during pain. Our findings indicate that the medications cilostazol and pentoxifylline have reduced relevance in the care of gait dysfunction even during pain in patients with PAD.

AB - Peripheral arterial disease (PAD) is a manifestation of atherosclerosis resulting in intermittent claudication (IC) or leg pain during physical activity. Two drugs (cilostazol and pentoxifylline) are approved for treatment of IC. Our previous work has reported no significant differences in gait biomechanics before and after drug interventions when PAD patients walked without pain. However, it is possible that the drugs are more efficacious during gait with pain. Our aim was to use advanced biomechanical analysis to evaluate the effectiveness of these drugs while walking with pain. Initial and absolute claudication distances, joint kinematics, torques, powers, and gait velocity during the presence of pain were measured from 24 patients before and after 12 weeks of treatment with either cilostazol or pentoxifylline. We found no significant improvements after 12 weeks of treatment with either cilostazol or pentoxifylline on the gait biomechanics of PAD patients during pain. Our findings indicate that the medications cilostazol and pentoxifylline have reduced relevance in the care of gait dysfunction even during pain in patients with PAD.

KW - Biomechanics

KW - Cilostazol

KW - Locomotion

KW - Pentoxifylline

KW - Peripheral arterial disease

UR - http://www.scopus.com/inward/record.url?scp=84862875609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862875609&partnerID=8YFLogxK

U2 - 10.1123/jab.28.2.184

DO - 10.1123/jab.28.2.184

M3 - Article

C2 - 22723116

AN - SCOPUS:84862875609

VL - 28

SP - 184

EP - 191

JO - Journal of Applied Biomechanics

JF - Journal of Applied Biomechanics

SN - 1065-8483

IS - 2

ER -